Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled ...
The recent run of good fortune for vaccine maker Novavax (NASDAQ:NVAX continues. Following the major licensing deal with ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi ...
Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's ...
Sanofi on Friday said it had reached a deal worth up to $1.2 billion to sell Novavax’s Covid shot as well as to try to ...
Sanofi has signed a $1.2bn licensing agreement with Novavax to co-commercialise its stand-alone adjuvanted Covid-19 vaccine.
STORY: Shares of vaccine maker Novavax spiked as much as 146% on Friday, after announcing it had struck a licensing deal with ...
Novavax (NASDAQ:NVAX) shares rocketed 40% in premarket trading Friday, driven not only by the company’s fiscal Q1 2024 ...
Novavax shares jumped 50% on Monday following its recent licensing deal with Sanofi, as meme stocks are making a 2021-style ...
On today's episode of The Morning Brief, Hosts Seana Smith and Brad Smith break down some of the biggest news affecting the ...
Novavax (NVAX) shares are skyrocketing after the company announced a $1.2 billion deal with French drugmaker Sanofi (SNY). B.
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled after Sanofi struck a licensing deal worth up to $1.2bn to commercialise ...